title: [The vaccinal prophylaxis of hepatitis B among children born to mothers with persistent HBs-antigenemia].
abstract: In Uzbekistan and Moldova 542 children born of HBsAg carriers were immunized against hepatitis B (with vaccine Engerix B according to the immunization schedule of 4 injections). Anti-HBs antibodies in protective titers were detected by EIA and RIA techniques in 76.7% of children aged 4-5 months after the 3rd injection, in 95.7% of children aged 15-16 months and in 90.0% of children aged 2-2.5 years after the 4th (booster) injection. In the control group (117 nonimmunized children born of HBs carriers) observed during the same period anti-HBs antibodies were detected significantly less frequently (in 7.3%, 11.6% and 12.9% of these children respectively). 1-2 months after the course of immunization was completed 74.1% of the immunized children had high anti-HBs antibody titers (exceeding 1000 IU/ml) with their subsequent decrease by 2-2.5 years of age. In the control group these figures were 27.1% and 29.0% respectively. The index of immunization effectiveness obtained by the comparison of the hepatitis B morbidity rates in both groups was 7.8. No postvaccinal complications were registered.
authors.forename: P A
authors.initials: PA
authors.lastname: Khukhlovich
authors.forename: I V
authors.initials: IV
authors.lastname: Shakhgil'dian
authors.forename: M I
authors.initials: MI
authors.lastname: Narkevich
authors.forename: V A
authors.initials: VA
authors.lastname: Anan'ev
authors.forename: S N
authors.initials: SN
authors.lastname: Kuzin
authors.forename: N A
authors.initials: NA
authors.lastname: Sergeeva
authors.forename: Sh Kh
authors.initials: ShKh
authors.lastname: Khodzhaev
authors.forename: P I
authors.initials: PI
authors.lastname: Iarovoĭ
authors.forename: Zh A
authors.initials: ZhA
authors.lastname: Drobeniuk
authors.forename: A K
authors.initials: AK
authors.lastname: Iuldashev
authors.forename: M A
authors.initials: MA
authors.lastname: Khodzhaeva
authors.forename: O N
authors.initials: ON
authors.lastname: Makmudova
authors.forename: A Ia
authors.initials: AIa
authors.lastname: Buriev
authors.forename: R A
authors.initials: RA
authors.lastname: Rakhimov
authors.forename: G M
authors.initials: GM
authors.lastname: Tuliaganova
authors.forename: V A
authors.initials: VA
authors.lastname: Khasanova
authors.forename: M I
authors.initials: MI
authors.lastname: Tsvaĭner
authors.forename: T S
authors.initials: TS
authors.lastname: Eliseeva
authors.forename: M A
authors.initials: MA
authors.lastname: Tuĭchibaeva
authors.forename: L V
authors.initials: LV
authors.lastname: Mineecheva
authors.forename: E I
authors.initials: EI
authors.lastname: Kotsaga
authors.forename: V I
authors.initials: VI
authors.lastname: Nagachevskaia
authors.forename: N Kh
authors.initials: NKh
authors.lastname: Rafikova
authors.forename: S M
authors.initials: SM
authors.lastname: Klimenko
mesh_terms: D000704:Analysis of Variance; D002353:Carrier State / Q000276:immunology*; D004341:Drug Evaluation; D005260:Female; D006509:Hepatitis B / Q000276:immunology* / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000009:adverse effects / Q000276:immunology*; D006513:Hepatitis B e Antigens / Q000097:blood; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008966:Moldova; D011247:Pregnancy; D014610:Uzbekistan; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology*
chemical_list: C075654:Engerix-B; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens; D014614:Vaccines, Synthetic
vernacular_title: Vaktsinoprofilaktika gepatita B sredi deteĭ, rodivshikhsia ot matereĭ s persistiruiushcheĭ HBs-antigenemieĭ.